Solrikitug

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug NameSolrikitug
Drug Alias NameMK-8226NSI-8226
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionThymic stromal lymphopoietin inhibitors
TargetsThymic stromal lymphopoietin
Therapy Area/IndicationsDermatitis, AtopicHypertensionPulmonary Disease, Chronic Obstructive +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesUniquity Bio
Inactive CompaniesMerck Sharp & Dohme LLC
Active IndicationsPulmonary Disease, Chronic ObstructiveAsthmaEosinophilic Esophagitis
Inactive IndicationsDermatitis, AtopicHypertension

Other Information

ATC CodeN/A
Related LinksN/A